Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00360763
Recruitment Status : Unknown
Verified August 2006 by Huazhong University of Science and Technology.
Recruitment status was:  Recruiting
First Posted : August 7, 2006
Last Update Posted : August 7, 2006
Information provided by:
Huazhong University of Science and Technology

Brief Summary:
The autoantibodies against AT1 receptor (ATR-AA), behaving like an agonist were detected in patients with hypertension. ATR-AA which can blocked by ARB may play a role in the pathogenesis of hypertension. The present study is to explore whether AT1 receptor blocker has superior anti-hypertensive effect in patients with positive ATR-AA hypertension. Patients with 2 grade hypertension were recruited and ATR-AA was assayed by ELISA. A study was carried out and the efficacy of anti-hypertension was compared between candesartan cilexetil and ACE inhibitor imidapril.

Condition or disease Intervention/treatment Phase
Hypertension Drug: candesartan cilexetil Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Completion Date : December 2006

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hypertension (2 grade)

Exclusion Criteria:

  • Secondary hypertension
  • Known sensitivity or intolerance to an angiotensin II receptor antagonist or ACE inhibitor
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00360763

Layout table for location information
China, Hubei
Department of Cardiology, Wuhan Union Hospital Recruiting
Wuhan, Hubei, China, 430022
Contact: Yu-Hua Liao, Doctor    00862785726376   
Sponsors and Collaborators
Huazhong University of Science and Technology
Layout table for investigator information
Study Director: Yu-Hua Liao Union Hospital, Tongji Medical College
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00360763    
Other Study ID Numbers: UH-01
First Posted: August 7, 2006    Key Record Dates
Last Update Posted: August 7, 2006
Last Verified: August 2006
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases
Candesartan cilexetil
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action